<DOC>
	<DOCNO>NCT01233375</DOCNO>
	<brief_summary>The purpose study determine whether CO-1.01 safe effective treat metastatic pancreatic cancer respond gemcitabine .</brief_summary>
	<brief_title>Study Evaluate Efficacy CO-1.01 Second Line Therapy Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>Pancreatic tumor low hENT1 expression may show less benefit gemcitabine compare high expression nucleoside transporter . Nonclinical study indicate CO-1.01 , gemcitabine derivative , effective independent transporter . Thus patient low meaningful expression hENT1 fail respond gemcitabine might derive benefit CO1.01 need alternative ( combination ) chemotherapy . Furthermore , PK profile CO-1.01 gemcitabine dissimilar may confer additional clinical benefit CO1.01 .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Gemcitabinerefractory metastatic ductal adenocarcinoma pancreas At least 1 measurable lesion accord RECIST 1.1 criterion Computerized tomography ( CT ) scan ≤ 28 day prior CO1.01 Firstline treatment include least 3 dos gemcitabine ( monotherapy combination therapy ) last dose administer least 2 week prior CO 1.01 Radiological best response disease progression 1stline treatment ( radiological stable disease well allow time ) Patients experience progressive disease ( neo ) adjuvant gemcitabinebased therapy also eligible Patients complete previous adjuvant therapy without progression , subsequently radiological best response disease progression 1st line gemcitabine metastatic disease eligible 2 . No hENT1 expression primary metastatic tumor sample , confirm IHC core pathology laboratory prior study entry also eligible 3 . Performance Status ( ECOG ) 0 1 4 . Age ≥18 year 5 . Palliative radiotherapy ( administer ) ≥2 week prior CO1.01 6 . Adequate hematological biological function , residual gemcitabinerelated toxicity 7 . Written consent Institutional Review Board ( IRB ) approve IC Form prior studyspecific evaluation 1 . Patients stable disease , partial response complete response first line gemcitabinebased therapy 2 . Firstline chemotherapy regimen contain gemcitabine 3 . Firstline treatment discontinue due intolerable gemcitabineinduced toxicity 4 . Second subsequent line therapy advance disease . Prior exposure CO1.01 prior randomization protocol study CO1.01 ( e.g. , Protocol CO101001 ) 5 . Tumor evaluate hENT1 expression hENT1 stain &gt; 50 % cell 6 . Symptomatic brain metastasis 7 . Concomitant treatment prohibit medication ( e.g. , concurrent anticancer therapy include chemotherapy , radiation , hormonal treatment [ except corticosteroid megestrol acetate ] , immunotherapy ) ≤14 day prior CO1.01 8 . Exploratory laparotomy , palliative ( e.g. , bypass ) surgery , procedure allow &lt; 14 day prior CO1.01 administration ; stenting procedure permissible time prior dosing ; case , patient must sufficiently recover stable 9 . History allergy gemcitabine egg 10 . Females pregnant breastfeed 11 . Refusal use adequate contraception fertile patient ( female male study 6 month last dose CO1.01 ) 12 . Presence serious unstable concomitant systemic disorder incompatible clinical study ( e.g. , substance abuse , psychiatric disturbance , uncontrolled intercurrent illness include active infection , arterial thrombosis , symptomatic pulmonary embolism ) 13 . Any reason investigator considers patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>pancreatic</keyword>
	<keyword>pancreas</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>human equilibrative nucleoside transporter-1 ( hENT1 )</keyword>
	<keyword>CO-1.01</keyword>
	<keyword>CO-101</keyword>
	<keyword>CO101</keyword>
	<keyword>Stage 4</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Gemcitabine-Refractory</keyword>
	<keyword>Second-Line Therapy</keyword>
</DOC>